Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 6/20 | 0.39 |
| ▸ | ATM | Q13315 | 4/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4371806 | 0.86 | PDE4D (0.33) | PDE4DKDM4EMAPT | |
| SCHEMBL13851127 | 0.85 | PDE4D (0.34) | PDE4DL3MBTL1EPHX2MTNR1AMTNR1B | |
| SCHEMBL3218428 | 0.80 | PDE4B (0.32) | PDE4DATMPDE4BMEN1KMT2A | |
| SCHEMBL3225282 | 0.79 | ATM (0.34) | PDE4DATMPDE4BMEN1KMT2A | |
| SCHEMBL24338716 | 0.73 | MTNR1A (0.38) | PDE4DEPHX2MTNR1AMTNR1B | |
| SCHEMBL3207493 | 0.73 | MEN1 (0.37) | PDE4DMEN1KMT2ACREBBP | |
| SCHEMBL3222747 | 0.70 | KDM4E (0.40) | PDE4DPDE4BMEN1KMT2AKDM4E | |
| SCHEMBL3222801 | 0.70 | PDE4D (0.41) | PDE4DKDM4EMAPTL3MBTL1TSHR | |
| SCHEMBL13851326 | 0.70 | MAOA (0.32) | — | |
| SCHEMBL13851037 | 0.68 | ALDH1A1 (0.32) | PDE4BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056791-A1 | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056791-A1 | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056791-A1 | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2060572-A1 | PYRAZOLOPYRIDINE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-05-20 | — | — | EP | disclosed |
| EP-2058310-A1 | PYRAZOLOPYRIDINE CARBOXAMIDE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR COMPRISING THE DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-05-13 | — | — | EP | disclosed |
| EP-2058310-A1 | PYRAZOLOPYRIDINE CARBOXAMIDE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR COMPRISING THE DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | PDE3A, PDE5A, PDE3B | PDE4D 16/4885ATM 2044/4885PDE4B 18/4885 |
| US-20100056791-A1 | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same | PDE5A, PDE3A, PDE2A | PDE4D 8/4885ATM 2389/4885PDE4B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.